1017 results about "Alcoholic fatty liver" patented technology

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-α and to improve insulin resistance in NAFLD patients.

The invention relates to compositions containing cholesterol absorption inhibitors alone or in combination with other therapeutic agents for treating non-alcoholic fatty liver disease-associated disorders by administering a therapeutically effective amount of the compositions to a subject in need thereof.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease using an ACC inhibitor alone or with one or more additional therapeutic agents.

The invention discloses high-fat feed and application thereof in building an animal model with non-alcoholic fatty liver. The high-fat feed comprises the following raw materials in mass percent: 80.5% of rat breeding feed, 10% of egg, 7% of lard oil, 2% of cholesterol and 0.5% of No.3 bile salt. The model built in the invention can subsequently experience former three stages in the development ofthe clinical disease course of the non-alcoholic fatty liver: simple fatty liver, steato hepatitis and fibrosis. The model is used for studying the pathogenesis as well as the development mechanism of the non-alcoholic fatty liver, studying the prevention and treatment of the non-alcoholic fatty liver at different stages, and particularly for screening new medicines for preventing and treating fibrosis of the non-alcoholic fatty liver, screening measures for preventing and treating fibrosis of the non-alcoholic fatty liver and objectively evaluating the methods for preventing and treating thenon-alcoholic fatty liver at each stage.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

A compound of Formula (I):

or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X¹ and X² are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

The invention discloses an ilicis routundae cortex medicinal composition for preventing and treating alcoholic liver damage, alcoholic fatty liver, non-alcoholic fatty liver and hyperlipidemia. The composition is extracted and refined from natural ilicis routundae cortex and is not chemically modified, and is characterized by comprising substances such as pedunculoside, syringin, rotundicacid and the like. The invention also discloses a preparation method of the ilicis routundae cortex composition and application to preparation of a medicament for preventing and treating the alcoholic liver damage, the alcoholic fatty liver and the non-alcoholic fatty liver and lowering blood fat.

The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates to methods of reducing the likelihood of a patient at risk for non-alcoholic fatty liver diseases (NAFLD), including non-alcoholic steatohepatitis (NASH), or treating NAFLD or NASH including primary NASH, NASH secondary to liver transplantation (NASH post-liver transplantation) or cirrhosis represent alternative aspects of the present invention.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The invention relates to preparation methods of sulphonylaminocarbonyl derivatives and compositions containing the same component and a use of the sulphonylaminocarbonyl derivatives as FXR and/or TGR5 agonists; the agonists are the sulphonylaminocarbonyl derivatives represented by the formula I, or pharmaceutically acceptable salts, prodrugs, solvates, hydrates, polymorphs, isomers, and stable isotope derivatives thereof. The compounds can be used for treatment of diseases and symptoms mediated by FXR and/or TGR5 and other therapeutic fields, wherein the diseases and symptoms include primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity.

The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:

which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

The invention discloses a method for establishing a non-alcoholic fatty liver disease combined with viral hepatitis mouse model. The method comprises the steps that high-fat feed is used for feeding a C3H/HeN small mouse for 12 weeks, the body weight, the liver weight, transaminase, the glucolipid metabolism index and liver histological change of the small mouse are observed, and a non-alcoholic fatty liver disease small mouse is cultivated. Then 10 PFU of MHV-3 infected mice are selected, and the survival rate, the liver histology and intrahepatic virus replication of the infected mice are observed, so that the non-alcoholic fatty liver disease combined with viral hepatitis mouse model similar to a human disease process is established. The established model provides a forceful tool for virus dynamics, immunological changes and prevention and control measures systematically studying non-alcoholic fatty liver disease combined with viral hepatitis.

A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.

The invention belongs to the field of biotechnology, and relates to a serum miRNA maker assemblage for detecting nonalcoholic fatty liver, and its application. The serum miRNA maker assemblage for detecting nonalcoholic fatty liver includes the following four has-microRNAs: hsa-miR-122-5p, hsa-miR-1290, hsa-miR-27b-3p and hsa-miR-192- 5p. The serum miRNA maker assemblage can realize early detection and rapid noninvasive detection of the nonalcoholic fatty liver.

The invention discloses lactobacillus reuteri capable of intervening in metabolic syndrome and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1145 screened by the invention can significantly improve the increase of serum total cholesterol content of metabolic syndrome mice caused by high fat diet. The weight rise of metabolic syndrome individuals is relieved, and the daily diet intake and the energy efficiency are remarkably reduced. Fasting blood glucose and insulin resistance index levels of metabolic syndrome individuals are significantly improved. The rise of Romboutsia in the intestinal tract caused by high fat diet is obviously relieved. The levels of anti-oxidative stress CAT and SOD in the liver are remarkably improved, serum lipopolysaccharide endotoxin is inhibited, and a colon barrier structure is maintained. The lactobacillus reuteri CCFM1145 disclosed by the invention can be used for preparing pharmaceutical compositions and fermented foods for relieving diseases such as metabolic syndrome, non-alcoholic fatty liver disease and diabetes mellitus and the like, and has a very wide application prospect.